Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2018.02.080
Abstract: It is now known that "gain of function" mutations of RET (REarranged during Transfection) kinase are specific and key oncogenic events in the onset of thyroid gland cancers such as the Medullary Thyroid Carcinoma (MTC).… read more here.
Keywords: medullary thyroid; challenging clinically; clinically unresponsive; ret inhibitors ... See more keywords
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016–present)
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2022.2132851
Abstract: ABSTRACT Introduction Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase. Aberrations in RET signaling due to mutations, gene fusions, or overexpression can lead to carcinomas. Six inhibitors have been approved for the treatment… read more here.
Keywords: kinase; ret inhibitors; ret; rearranged transfection ... See more keywords
Abstract 1842: Novel KIF5B-RET+ NSCLC cell lines demonstrate differential responses to RET inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-1842
Abstract: Chromosomal rearrangements involving the rearranged during transfection (RET) tyrosine kinase occur in 1-2% of NSCLCs. This results in the expression of a constitutively active fusion kinase that promotes cancer cell growth, proliferation and survival. In… read more here.
Keywords: ret inhibitors; kif5b ret; cell lines; cell ... See more keywords
Abstract 4264: The genomic landscape of RET fusions in non-small cell lung cancer and the impact of co-occurring genomic alterations on the efficacy of selective RET inhibitors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4264
Abstract: Purpose: RET fusions drive oncogenesis in 1-2% of non-small cell lung cancer (NSCLC) and are sensitive to the selective RET inhibitors selpercatinib and pralsetinib. They have also emerged as mechanisms of acquired resistance to other… read more here.
Keywords: genomic alterations; ret inhibitors; ret; selective ret ... See more keywords
Prognostic factors in RET dependent cancers treateded with RET inhibitors in early phase clinical trials.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3117
Abstract: 3117 Background: Activation of the RET proto-oncogene has been identified in multiple cancer types, for example, gene rearrangements in non-small cell lung cancer (NSCLC) and papillary thyroid cancer (PTC) and activating mutations in medullary thyroid… read more here.
Keywords: associated inferior; cancer; pfs; ret inhibitors ... See more keywords
RET Inhibitors in Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13174415
Abstract: Simple Summary Non-small cell lung cancer (NSCLC) remains a significant cause of death worldwide, despite the significant progresses to date. Multiple molecular alterations have been identified in NSCLC, leading to the development of target-based agents… read more here.
Keywords: nsclc; non small; ret inhibitors; small cell ... See more keywords